1. Norway Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Photocure ASA

Photocure ASA

PHO.OL
Photocure ASANO flagOslo Stock Exchange
58.80
NOK
- -
- -
1.56BMarket Cap
Photocure ASA
PHO.OL
(Oslo Stock Exchange)

Recent

price

58.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
8.22
5.34
6.29
3.94
6.05
6.3
6.68
7
8.41
12.93
10.42
13.43
14.54
18.47
19.38
19.98
20.69
Revenue per Share
0.84
-0.35
-2.25
-2.78
-1.16
-1.69
1.64
-1.61
-1.7
1.46
-0.91
-1.15
-2.66
0.04
-0.12
-0.06
-0.21
Basic EPS, GAAP
0.67
-1.79
-2.65
-4.75
-0.33
-1.68
-0.14
-1.96
-1.22
0.9
0.57
0.75
-0.21
1.02
2.08
-0.38
1.36
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
17.92
17.17
14.45
11.03
9.49
7.81
9.17
7.44
5.22
6.63
5.04
3.5
0.83
0.82
0.89
-0.44
-0.19
Book Value per Share
21.26
20.57
17.88
12.66
11.26
9.26
10.49
8.57
7.13
9.05
8.12
7.88
6.95
8
9.09
8.71
9.14
Tangible Book Value per Share
22
21
21
21
21
21
22
22
22
22
25
27
27
27
27
27
25
Basic Weighted Avg Shares
177
114
134
84
129
135
144
151
182
282
256
361
393
501
525
533
523
Sales/Revenue/Turnover
4.24
-26.82
-29.33
-85.92
-4.37
-16.32
-11.04
-29.95
-13.06
15.18
-9.05
-1.62
-12.46
5.55
3.88
-0.14
0.17
Operating Margin (%)
1
1
2
1
1
4
8
12
13
16
19
24
24
28
29
29
29
Depreciation Expense
18
-8
-48
-59
-25
-36
35
-35
-37
32
-22
-31
-72
1
-3
-2
-5
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
30.65
- -
- -
- -
89.95
139.8
- -
467.32
Effective Tax Rate (%)
10.2
-6.58
-35.79
-70.5
-19.15
-26.85
24.58
-22.99
-20.22
11.31
-8.73
-8.57
-18.28
0.2
-0.64
-0.28
-1.02
Profit Margin (%)
373
313
277
167
167
170
182
135
101
148
332
300
254
289
320
274
293
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
7
41
36
21
14
11
5
- -
LT Debt
459
439
380
269
240
210
252
218
176
209
508
503
463
483
502
484
480
Total Equity
1.71
- -
- -
- -
- -
- -
- -
- -
- -
14.81
- -
- -
- -
0.54
-1.56
- -
- -
Return on Invested Capital (%)
6.35
- -
- -
- -
- -
- -
- -
- -
- -
24.24
- -
- -
- -
5.98
-28.74
- -
-131.22
Return on Capital (%)
5.07
-1.99
-14.22
-21.77
-11.31
-19.6
19.39
-19.41
-26.89
24.77
-16.69
-28.33
-123.57
4.39
-14.38
- -
49.69
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
16
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
11
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
27
27
27
Market Capitalization
1,577
1,423
1,367

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
424
392
371
Cash, Cash Equivalents & STI
289
260
239
Accounts Receivable, Net
67
68
73
Inventories
40
38
38
Total Current Liabilities
104
103
78
Payables & Accruals
- -
- -
- -
ST Debt
16
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.5%
-0.85%
-3.49%
Free Cash Flow
32.57%
-138.36%
-118.02%
Net Income, GAAP
-117.38%
-85.32%
-54.58%
Sales/Revenue/Turnover
16.14%
16.65%
1.37%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
118
145
120
142
525
2025
125
136
137
- -
533
2026
265
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.29
0.45
-0.13
-0.21
-0.12
2025
-0.09
0.18
-0.3
- -
-0.06
2026
3.14
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Oxford Biomedica plc (OXB.L)
GH Research PLC (GHRS)
Geron Corporation (GERN)
Alpine Immune Sciences, Inc. (ALPN)
Nanobiotix S.A. (NBTX)
Abivax S.A. (0RA9.L)
Business
Photocure ASA, a specialized pharmaceutical firm, concentrates its efforts on the research, development, manufacturing, sales, and global promotion of innovative pharmaceutical solutions. The company maintains a commercial presence across the Nordic regions, Germany, France, Austria, the United Kingdom, the Benelux countries, Italy, other European territories, Canada, and the United States. Its primary offering, Hexvix®/Cysview®, employs a unique photodynamic technology to enhance the visualization and management of bladder cancer during blue light cystoscopy, making cancer cells illuminate with a distinct pink glow. Additionally, Photocure has licensed Cevira®, a drug-device combination for the non-surgical management of human papillomavirus-induced pre-cervical lesions, to its partner Asieris Meditech Co., Ltd., which is currently undergoing regulatory review in China. The company distributes its core products to pharmaceutical wholesalers, pharmacies, and hospitals through both direct sales teams and strategic licensing collaborations. Established in 1993, Photocure ASA is headquartered in Oslo, Norway.